Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro Public Deposited

http://ir.library.oregonstate.edu/concern/articles/qz20sv12s

This is the publisher’s final pdf. The published article is copyrighted by the author(s) and published by BioMed Central. The published article can be found at:  http://bmcvetres.biomedcentral.com/

Descriptions

Attribute NameValues
Creator
Abstract or Summary
  • Background: Canine oral fibrosarcoma (COF) is one of the most common oral tumors in dogs and carries a guarded prognosis due to a lack of effective systemic therapeutic options. Mastinib and imatinib are two commonly used tyrosine kinase inhibitors (TKIs) in veterinary oncology but their potential efficacy against COF is uncharacterized. To begin investigating the rationale for use of these TKIs against COF, the present study tested for the presence TKI targets PDGFR-α, PDGFR-β, Kit, and VEGFR-2 and examined the in vitro effects on cell viability after TKI treatment alone or with doxorubicin. Immunohistochemistry for PDGFR-α, PDGFR-β, Kit, and VEGFR-2 was performed in 6 COF tumor biopsies. Presence of these same receptors within 2 COF cell lines was probed by reverse transcription-polymerase chain reaction and, for those with mRNA detected, confirmed via western blot. Effects on cell viability were assessed using an MTS assay after masitinib or imatinib treatment alone (0-100 μM), or in combination with doxorubicin (0-3000 nM doxorubicin). Anti-PDGFRB siRNA knockdown was performed and the effect on cell viability quantified. Results: Expression of the TKI targets evaluated was similar between the 2 COF cell lines and the 6 COF tumor biopsies: PDGFR-α and PDGFR-β were detected in neoplastic cells from most COF tumor biopsies (5/6 and 6/6, respectively) and were present in both COF cell lines; KIT and KDR were not detected in any sample. Masitinib and imatinib IC50 values ranged from 7.9–33.4 μM, depending on the specific TKI and cell line tested. The addition of doxorubicin resulted in synergistic cytotoxicity with both TKIs. Anti-PDGFRB siRNA transfection reduced PDGFR-β protein expression by 77 % and 67 % and reduced cell viability by 24 % (p < 0.0001) and 28 % (0 = 0.0003) in the two cell lines, respectively. Conclusions: These results provide rationale for further investigation into the use of TKIs, possibly in combination with doxorubicin, as treatment options for COF.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Milovancev, M., Helfand, S. C., Marley, K., Goodall, C. P., Löhr, C. V., & Bracha, S. (2016). Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro. BMC Veterinary Research, 12, 85. doi:10.1186/s12917-016-0712-x
Series
Keyword
Rights Statement
Funding Statement (additional comments about funding)
Publisher
Peer Reviewed
Language
Replaces
Additional Information
  • description.provenance : Made available in DSpace on 2016-06-28T15:59:33Z (GMT). No. of bitstreams: 2 krauserp1934384625.zip: 2400215 bytes, checksum: 5dc8084dbe33adde5ba44b9b22798280 (MD5) MilovancevAntiproliferativeEffectsofMasitini.pdf: 2516284 bytes, checksum: d3756babf2eb6ecafef2e2691ec48599 (MD5) Previous issue date: 2016-06-04
  • description.provenance : Submitted by Open Access (openaccess@library.oregonstate.edu) on 2016-06-27T16:48:55Z No. of bitstreams: 1 MilovancevAntiproliferativeEffectsofMasitini.pdf: 2516284 bytes, checksum: d3756babf2eb6ecafef2e2691ec48599 (MD5)
  • description.provenance : Approved for entry into archive by Patricia Black(patricia.black@oregonstate.edu) on 2016-06-28T15:59:33Z (GMT) No. of bitstreams: 2 krauserp1934384625.zip: 2400215 bytes, checksum: 5dc8084dbe33adde5ba44b9b22798280 (MD5) MilovancevAntiproliferativeEffectsofMasitini.pdf: 2516284 bytes, checksum: d3756babf2eb6ecafef2e2691ec48599 (MD5)

Relationships

In Administrative Set:
Last modified: 06/27/2016

Downloadable Content

Download PDF
Citations:

EndNote | Zotero | Mendeley

Items